Paysign’s Q2 Earnings Call: Apherion FDA Timeline and Q3 Growth Claims Don’t Match

<<>>

Date of Call: Aug 5, 2026

Financials Results

• Revenue: $28.3 million, up 48% YOY
• EPS: $0.11 per fully diluted share, a near five-fold increase YOY
• Gross Margin: 63.3%, expanded 170 basis points YOY
• Operating Margin: 21.3% (adjusted), expanded more than 1,300 basis points YOY

Guidance:

• Full-year 2026 revenue expected to be $114 million to $117 million, representing 39% to 43% YOY growth, an increase of ~$7 million at the midpoint.
• Full-year gross profit margin expected between 62% and 63%, up from prior guidance of 60% to 62%.
• Full-year GAAP net income expected $21.5 million to $23 million, or $0.35 to $0.37 per diluted share.
• Full-year adjusted EBITDA expected $35 million to $38 million, or $0.57 to $0.61 per diluted share.
• Q3 2026 revenue expected $28.5 million to $30 million, up 32% to 38.9% YOY.
• Q3 gross margin expected 61% to 63%.
• Q3 GAAP net income expected $5.7 million to $6.0 million, or $0.09 to $0.10 per diluted share.
• Q3 adjusted EBITDA expected $9.5 million to $10 million, or $0.15 to $0.16 per diluted share.
• Expect to exit Q3 with 165 to 170 active patient affordability programs.
• Active plasma center count expected to slightly increase from Q2.

Business Commentary:

Record Financial Performance:

• PaySign Inc. reported record revenue of $28.3 million for the second quarter of 2026, up 48% year-over-year, with net income of $6.8 million, or $0.11 per fully diluted share, marking a near five-fold increase from the previous year.
• The growth was driven by strategic investments in patient affordability, which complemented plasma operations and augmented overall growth.

Patient Affordability Segment Growth:

• The patient affordability segment reported revenue of $14.6 million, up 89% year-over-year, with claim volume approximately 54% higher than the second quarter of the previous year.
• This growth was attributed to new program wins, deeper utilization of existing client programs, and the expansion of the largest pharmaceutical partnerships.

Plasma Business Recovery:

• Plasma revenue increased 21.4% year-over-year to $13 million, with monthly revenue per center reaching $7,699, the strongest since the third quarter of 2024.
• The improvement was driven by stronger donor utilization at existing centers, indicating a recovery from previous inventory-related headwinds.

Margin Expansion and Operating Leverage:

• Gross margin expanded by 170 basis points to 63.3%, and adjusted operating margin improved by more than 1,300 basis points to 21.3%.
• This was due to a greater mix of higher-margin patient affordability revenue and cost control measures, demonstrating operating leverage.

Strategic Outlook and Guidance Increase:

• PaySign raised its full-year 2026 guidance, expecting revenue of $114 million to $117 million, representing 39% to 43% year-over-year growth.
• The increase was driven by stronger-than-expected patient affordability performance and a recovery in the plasma business, reflecting confidence in sustainable growth and long-term value.

Sentiment Analysis:

Overall Tone: Positive

• Management stated: 'the second quarter validated the strategy we have been building towards the past several years. Patient affordability is scaling, plasma is steady and cash generative... we head into the back half of the year with business accelerating, margins expanding, and a pipeline that reaches into 2027. This is a business that's ramping, not just beating a number.' They also noted exceeding guidance and raising the full-year outlook.

Q&A:

• Question from Gary Prestapino (Barrington Research): Have you measured organic revenue growth per program on a same-store basis for programs with a 12-month history?
  Response: On a mature program with no new features, revenue is roughly flattish YOY; growth comes from adding new features, services, or indications.

• Question from Gary Prestapino (Barrington Research): Is the estimate of ~850 potential pharmaceutical programs still accurate?
  Response: The total addressable market is much larger, in the tens of thousands of branded products, biosimilars, and medical devices; the company is still in the early stages.

• Question from Gary Prestapino (Barrington Research): What is the status and timeline for the Aetherion (blood establishment software) regulatory approval?
  Response: Awaiting FDA regulatory review; the process is ongoing with no firm timeline, but there is strong domestic and international interest.

• Question from Jacob Stephan (Lake Street Capital Markets): Why is Q3 program addition guidance (~20) seasonally strong given Q3 is typically a lower quarter?
  Response: Q3 and Q4 are typically stronger as sales work begun in Q1 (around the Asymbia conference) leads to implementations; many programs are launched before Q1's insurance deductible resets to avoid transitions during the busy season.

• Question from Jacob Stephan (Lake Street Capital Markets): How does first-year revenue per program compare to seasoned programs, and is Dynamic Business Rules (DBR) included in initial launches?
  Response: DBR is typically included in initial launches for specialty products impacted by maximizers; revenue per program varies widely based on drug efficacy, manufacturer pipeline, and market competition, making generalizations difficult.

• Question from Peter Heckman (D.A. Davidson): What is the sales cycle and win rate for new programs, and is there seasonality to program wins?
  Response: ~75% of wins come from RFPs/RFIs (with a win rate north of 80%), and ~25% from direct awards; there is seasonality to program transitions (avoiding Q1 blizzard season), but selling activity is consistent year-round with key conferences like Asymbia in April-May driving momentum.

• Question from Peter Heckman (D.A. Davidson): Why is Q3 margin expected to be strong while Q4 appears weaker on an absolute dollar basis?
  Response: Q4 typically sees fewer program launches (as many are completed before Q1), plus some softness from holiday-related impacts on software development and higher tax rates; the company is hiring to prepare for the Q1 launch surge.

• Question from John Hickman (Annenberg Thalmann): Is 15% YOY growth a reasonable expectation for operating expenses going forward?
  Response: 15% to 20% growth is not unreasonable given the need to hire for the growing patient affordability business as program counts increase.

• Question from John Hickman (Annenberg Thalmann): Are you attending any upcoming conferences?
  Response: Yes, attending conferences in New York (September), Chicago (August IDEAS), and others, along with non-deal roadshows in Boston and New York.

Contradiction Point 1

Apherion Regulatory Approval Timeline

Inconsistent statements about the timeline and status of FDA approval for the Apherion platform, impacting investor expectations on product readiness.

Gary Prestapino (Barrington Research) - Gary Prestapino (Barrington Research)

2026Q2: The regulatory review process with the FDA is ongoing, and no specific timeline can be given. - Matt Lanford(CPO)

Okay, let's see. The user wants me to rewrite the input into a concise earnings-call question. The input is "Can you provide an update on the Aetherion (blood establishment software) regulatory approval process?" First, I need to make sure I follow the rules. The output must be exactly one line, only the final question text, end with a question mark if possible. No explanations or meta text.The original input is already a question, so I need to check if it's concise enough for an earnings call. Earnings call questions are usually very direct and to the point. The original question is about an update on the regulatory approval process for Aetherion, which is blood establishment software. Is there a way to make this more concise? The original is already pretty straightforward. Maybe "regulatory approval status" instead of "process"? Let me see. "Regulatory approval status" might be a bit shorter. So, "Can you provide an update on the regulatory approval status of Aetherion (blood establishment software)?" That's a bit more concise.But wait, the user mentioned to output exactly as-is if it's too vague or lacks info. The original input is clear. Maybe the original is acceptable. Let me check the rules again. The user says to output exactly one line, only the final question, end with "?" if possible. The original ends with "?", so if the rewrite is possible, it must end with that. I think the original is already a good question. Maybe the parentheses can be removed if the context is clear, but the user included "(blood establishment software)" which might be necessary for clarity. If I remove that, the question becomes "Can you provide an update on the Aetherion regulatory approval process?" But without the parenthetical, is it still clear? Maybe not. The original includes the product name and its purpose. So keeping the parentheses is better for clarity.So the original input is already a clear, concise question. Therefore, according to the rules, if it's already a clear question, I can output it as is. But wait, the user says to rewrite into one concise earnings-call question. The original is already a question. But maybe it's not concise enough. Earnings call questions are usually very direct. Let me think. The original is "Can you provide an update on the Aetherion (blood establishment software) regulatory approval process?" Maybe rephrase to "What is the current status of the regulatory approval process for Aetherion (blood establishment software)?" That's slightly more direct. But the user wants exactly one line. Both versions are one line. Which is more concise? The original uses "provide an update on", while "current status" is shorter. But the user's instruction is to rewrite into one concise question. The original is already a question. But maybe the user wants it to be as concise as possible. Let me compare:Original: Can you provide an update on the Aetherion (blood establishment software) regulatory approval process?Rewritten: What is the current status of Aetherion's (blood establishment software) regulatory approval?But the original mentions "regulatory approval process", the rewritten is "regulatory approval". Hmm. Maybe "process" is important. Alternatively: "Can you provide an update on the regulatory approval status of Aetherion (blood establishment software)?" That's slightly shorter than the original. The original says "approval process", this says "approval status". Both are acceptable. The user might prefer the most concise version. But since the original is already a valid question, and the user says if the input is already a question and clear, output as is. Wait, the user says: "If the input is NOT a question, is too vague, or lacks enough information to form a clear earnings-call question, output the input EXACTLY as-is, with no modification." But if it is a question, but can be rewritten into a more concise one, then we should do that. The original is a question, but maybe it's not concise enough. So the answer is to rewrite it into a more concise question. So the best approach is to rephrase the original question into a more concise one, ending with a question mark. Final version: "What is the current status of Aetherion's (blood establishment software) regulatory approval?" But maybe "regulatory approval process status" is better. Alternatively, "Can you provide an update on Aetherion's (blood establishment software) regulatory approval status?" Comparing the original and this version: the original is longer. The rewritten version replaces "provide an update on the... regulatory approval process?" with "provide an update on... regulatory approval status?" Which is more concise? The rewritten version is slightly shorter. So the answer should be the rewritten version. Therefore, the output should be: "Can you provide an update on Aetherion's (blood establishment software) regulatory - Gary Prestopino (Barrington Research)

2026Q2: The Apherion platform... is undergoing the regulatory review process, specifically awaiting FDA approval. The timeline is uncertain, but there is strong domestic and international interest. - Matt Lanford(CPO) and Jeff Baker(CFO)

Contradiction Point 2

Seasonal Pattern of Program Launches

Contradiction on whether Q3 is a typical or atypical quarter for program additions, affecting expectations for sequential business performance.

Jacob Stephan (Lake Street Capital Markets) - Jacob Stephan (Lake Street Capital Markets)

2026Q2: Q3 is not unusually strong; it follows normal timing. - Matt Turner(President of Patient Affordability)

Why is Q3 program addition guidance relatively strong seasonally, and does this indicate a different pipeline? - Jacob Stephan (Lake Street Capital Markets)

2026Q2: Q3 implies roughly 20 new program additions. That's strong seasonally. What gives you confidence in that strong sequential number for Q3, given Q4 is typically stronger? - Jacob Stephan (Lake Street Capital Markets)

Contradiction Point 3

Status and Timeline for SaaS/app (Aetherion) Regulatory Approval and Readiness

Contradiction on whether the SaaS platform is live, generating revenue, and FDA-approved, which is critical for assessing current revenue streams and product maturity.

Gary Prestapino (Barrington Research) - Gary Prestapino (Barrington Research)

2026Q2: The regulatory review process with the FDA is ongoing... The company is receiving strong domestic and international interest and will provide updates as milestones are met. - Matt Lanford(CPO)

What is the current status of the Aetherion regulatory approval process? - Jon Hickman (Ladenburg Thalmann)

2026Q1: The SaaS platform is not yet generating revenue. The company is currently in discussions with the FDA and expects to provide updates as soon as possible. - Mark Newcomer(CEO)

Contradiction Point 4

Growth Expectations for the Total Addressable Market for Pharmaceutical Programs

Contradiction on the size of the addressable market for pharmaceutical affordability programs, influencing strategic and investment outlook.

Could you provide an update on the company's financial performance and key strategic initiatives? - Gary Prestapino (Barrington Research)

2026Q2: The total addressable market is much larger. There are tens of thousands of drugs with copay programs... - Matt Turner(President of Patient Affordability)

Is the 850-900 potential pharmaceutical programs estimate still accurate? - Gary Prestopino (Barrington Research)

2026Q1: Clarified counts: they exited Q1 with 135 pharma programs (now at 141) and expect 147-150 active programs by end of Q2. - Jeff Baker(CFO)

Contradiction Point 5

Total Addressable Market (TAM) for Patient Affordability

Contradiction on the size of the addressable market, affecting strategic planning and investor perception of growth potential.

Gary Prestapino (Barrington Research) - Gary Prestapino (Barrington Research)

2026Q2: The total addressable market is much larger. There are tens of thousands of drugs with copay programs... - Matt Turner(President of Patient Affordability)

Okay, let's see. The user wants me to rewrite the input into a single concise earnings-call question. The input is: "Is the estimate of 850-900 potential pharmaceutical programs still accurate?" First, I need to check if this is already a clear question. It seems to be asking about the accuracy of a specific estimate. The numbers are 850-900, which are specific. The key elements here are "estimate," "pharmaceutical programs," and "still accurate." The rules say to output exactly one line, only the final question text, ending with a question mark if possible. Also, if the input isn't a question or is too vague, I should leave it as-is. But this input is already a question, so I need to make sure it's concise.The original question is already pretty concise. Maybe check if "potential pharmaceutical programs" is the right term. Maybe "pharmaceutical programs" could be ambiguous, but in the context of an earnings call, it's likely referring to programs they're working on. Since the input is a question and specific, maybe no changes are needed. The user's instruction says to output exactly as-is if it's a clear question. Wait, the rule says if it's not a question, too vague, or lacks info, output as-is. But if it's a valid question, rewrite into a concise one. Wait, the instruction says "rewrite the input into one concise earnings-call question." So even if it's a valid question, I need to rephrase it to be more concise, but still retain the meaning.The original question is: "Is the estimate of 850-900 potential pharmaceutical programs still accurate?" Maybe "potential" can be removed if it's redundant. Or "pharmaceutical programs" could be "programs" if the context is clear. But in an earnings call, they might refer to "pharmaceutical programs" as part of their business. So perhaps the original is already concise. Alternatively, maybe "Is the 850-900 estimate for pharmaceutical programs still accurate?" That's slightly shorter. But the user wants exactly one line and only the final question. Let me check the original again. The input is a valid question, so according to the rules, if it's a valid question with enough info, I should rewrite it into a concise version. The original is already concise, so maybe no changes needed. Wait, the instruction says "rewrite the input into ONE concise earnings-call question." So maybe the original is acceptable. But maybe "potential" can be omitted if it's implied. Alternatively, maybe "pharmaceutical programs" can be "programs" if the context is clear. But without knowing the context, it's safer to keep "pharmaceutical." So the final question would be: "Is the 850-900 estimate for pharmaceutical programs still accurate?" That's a bit more concise. But the original uses "estimate of 850-900 potential pharmaceutical programs." The word "potential" might be important. If the original includes "potential," maybe it's better to keep it. However, the user wants it concise. So maybe "potential" can be removed if it's not essential. But I don't want to change the meaning. Let me check again. The original is a question about the accuracy of the estimate. The term "potential" might indicate that these programs are in the planning or early stages. Removing it might change the meaning. So better to keep it. Therefore, the original is already concise and accurate. So according to the rules, if the input is a clear question with enough info, output as-is. Wait, the instruction says if it's a question, but needs to be rewritten into a concise one. Wait, the first rule says "rewrite the input into ONE concise earnings-call question." So even if the input is a question, I need to rephrase it to be more concise. The original is a valid question, but maybe can be made more concise. Let's try: "Is the 850-900 estimate for potential pharmaceutical programs still accurate?" That's the same as the original but slightly reordered. The original is "Is the estimate of 850-900 potential pharmaceutical programs still accurate?" Changing "of" to "for" might make it more concise. So the answer would be: "Is the 850-900 estimate for potential pharmaceutical programs still accurate?" But the user's input is the original. So the task is to rewrite it into a concise question. The original is already a question. So perhaps the answer is the original input, but the user wants it rewritten. Wait, the instruction says "rewrite the input into ONE concise earnings-call question." So regardless of whether it's already a question, I need to rephrase it to be concise. So perhaps the answer is the original - Jon Hickman (Ladenburg Thalmann)

20260325-2025 Q4: The estimated TAM is $500-$850 million, potentially expandable to $1 billion with new offerings. - Matthew Turner(President of Patient Affordability) / Mark Newcomer(CSO) / Jeffery Baker(CFO)

<<>>